Complications of Treatment, Progression
Conditions
Keywords
trabeculectomy, bevacizumab, anti-VEGF, Efficacy
Brief summary
Bevacizumab is an anti vascular endothelial growth factor(anti-VEGF) substance that is known to reduce neovascularization and fibrovascular proliferation in inflammatory conditions, including post-operative inflammation. It has shown efficacy in numerous ocular conditions(off-label), that includes Age related macular degeneration, proliferative diabetic retinopathy, neovascular glaucoma and corneal neovascularization. It is being explored as an option for preventing recurrence of pterygium and as an adjunct to improving outcomes of trabeculectomy. There is a debate as to the mode and duration of bevacizumab administration for trabeculectomy. This study aims to compare a single subconjunctival dose of bevacizumab with topical therapy over one month in terms of outcomes of trabeculectomy surgery, non-progression of field loss and stable intraocular pressure(IOP) control.
Interventions
PROCEDUREPhacoemulsification
Surgery for complications of trabeculectomy
Sponsors
Sudhalkar Eye Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
42 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Primary Open Angle Glaucoma * Progression * Failure to reach target IOP * Non compliant
Exclusion criteria
* Resurgery * Systemic contraindication to bevacizumab * All other forms of glaucoma
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Intraocular pressure control | For 2 years |
Secondary
| Measure | Time frame |
|---|---|
| Progression | 2 years |
Outcome results
None listed